[Indications of the association of radiotherapy and hormonal treatment in prostate cancer]. / Place de l'association de radiothérapie et d'hormonothérapie dans les cancers de la prostate.
Cancer Radiother
; 9(6-7): 394-8, 2005 Nov.
Article
en Fr
| MEDLINE
| ID: mdl-16226044
ABSTRACT
RTOG and EORTC randomised phase III trials investigated combination of radiation therapy and hormonal treatment in locally advanced prostate cancer T2c-T4 N0-1 M0 (UICC 2002). Complete androgen blockade initiated 2 months prior to starting radiotherapy and stopped at the completion of radiotherapy vs radiation therapy alone, increased overall survival in patients with Gleason score 2-6. Adjuvant androgen suppression started at the end of the radiotherapy and continued indefinitely improved significantly overall survival of patients Gleason score 8 to 10. Complete androgen blockade in two months before and two months during radiation followed by 24 additional months of LHRH analogue alone improved overall survival of patients Gleason score 8-10 with respect to CAB alone. EORTC trial 22861 has shown that androgen suppression with LHRH analogue given during and for 3 years after external irradiation improved overall survival whatever the Gleason score. The role of hormonal treatment is currently assessed in localized prostate cancer (T1-2 N0) with poor prognostic factors Gleason score 8-10, PSA>20 ng/ml.
Buscar en Google
Colección:
01-internacional
Asunto principal:
Neoplasias de la Próstata
/
Antagonistas de Andrógenos
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
/
Male
Idioma:
Fr
Revista:
Cancer Radiother
Asunto de la revista:
NEOPLASIAS
/
RADIOTERAPIA
Año:
2005
Tipo del documento:
Article
País de afiliación:
Francia